(Q51978424)

English

Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persi

scientific article published on 2 October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persi (English)

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

0 references

0 references

1 reference

based on heuristic

inferred from title

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

based on heuristic

inferred from title

object named as

poliovirus

1 reference

based on heuristic

inferred from title

author name string

U Heininger

1

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

DTP-HBV-IPV-059 Study Group

2

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

DTP-HBV-IPV-096 Study Group

3

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

R Sänger

4

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

J-M Jacquet

5

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

L Schuerman

6

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

language of work or name

0 references

publication date

2 October 2006

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

25

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

6

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

1055-1063

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Hepatitis B: vaccination programmes in Europe--an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Development and clinical application of new polyvalent combined paediatric vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Clinical relevance of lower Hib response in DTPa-based combination vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety of combination vaccines: perception versus reality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Antibody responses and reactions to the whole cell pertussis component of a combined diphtheria/tetanus/pertussis vaccine given at school entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.060

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.09.060

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

1 reference

Europe PubMed Central

19 April 2018

http://europepmc.org/abstract/MED/17049692

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51978424&oldid=2164019801"